apolizumab
mAbexperimental
Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers. Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia. — Wikipedia
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1999 (NCT00004101)
Timeline
Indications
Studied for
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
HLA-DRA inhibitor
Human leukocyte antigen DR beta chain inhibitor
- HLA class II histocompatibility antigen, DRB1-1 beta chain ↗
- HLA class II histocompatibility antigen, DR beta 3 chain (HLA-DRB3) ↗
- HLA class II histocompatibility antigen, DRB1-3 chain ↗
- HLA class II histocompatibility antigen, DRB1-9 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-12 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-10 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-13 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-8 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-16 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-4 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-7 beta chain ↗
- HLA class II histocompatibility antigen, DR beta 5 chain (HLA-DRB5) ↗
- HLA class II histocompatibility antigen, DRB1-15 beta chain (HLA-DRB1) ↗
- HLA class II histocompatibility antigen, DRB1-14 beta chain ↗
- HLA class II histocompatibility antigen, DRB1-11 beta chain ↗
- HLA class II histocompatibility antigen, DR beta 4 chain (HLA-DRB4) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaApolizumab ↗
- ChEMBLCHEMBL2108252 ↗
Also known as
- apolizumab
- apolizumab
- apolizumab
- hu1d10
- hu1d10
- hu1d 10
- remitogen
- remitogen smart1d10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00089154 | Phase 2 | Aug 1, 2004 | National Cancer Institute (NCI), Ohio State University |
| NCT00055783 | Phase 2 | Jul 1, 2002 | National Cancer Institute (NCI), Stanford University |
| NCT00022971 | Phase 1 | Aug 15, 2001 | National Cancer Institute (NCI) |
| NCT00017472 | Phase 1 | Apr 1, 2001 | National Cancer Institute (NCI), Ohio State University |
| NCT00014664 | Phase 2 | Oct 1, 2000 | Facet Biotech, PDL BioPharma |
| NCT00004101 | Phase 1 | Nov 1, 1999 | National Cancer Institute (NCI), University of Iowa |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 5 | 4 | 2 | 1999 |
| Ohio State University | Academic/Hospital | 2 | 0 | 2 | 2001 |
| Facet Biotech | For profit | 1 | 0 | 1 | 2000 |
| PDL BioPharma | For profit | 1 | 1 | 1 | 2000 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 1999 |
6 organizations
Page 1 / 1